Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🔥 This hedge fund gained 26.16% in the last month. Get their top stocks with our free stock ideas tool.See stock ideas

Roche's Actemra successful in late-stage study in giant cell arteritis

Published 11/13/2016, 09:51 PM
Roche's Actemra successful in late-stage study in giant cell arteritis
RHHBY
-
  • A Phase 3 clinical trail, GiACTA, assessing Roche unit Genentech's (OTCQX:RHHBY) Actemra (tocilizumab) for the treatment of giant cell arteritis (GCA) met its primary efficacy endpoint. The data were presented at the American College of Rheumatology and Association of Rheumatology Health Professionals Annual Meeting in Washington, D.C.
  • Tocilizumab, initially combined with a six-month steroid taper regimen, demonstrated superiority to a six-month steroid taper regimen alone as measured by the proportion of patients achieving sustained remission at one year. Specifically, 56% of patients in the once/week dose cohort and 53.1% of patients in the once-every-other week dose cohort achieved sustained remission at Year 1 compared to 14% for the six-month steroid taper regimen alone. No new safety signals were observed.
  • According to ClinicalTrials.gov, the estimated study completion date is April 2018.
  • GCA is an inflammation of the lining of the arteries, typically those in the temples. If untreated, it can lead to stroke or blindness. It affects ~0.2% of Americans over the age of 50.
  • Actemra is currently approved for the treatment of certain kinds of arthritis.

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.